BCRX FY 2022 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$271M+72.3% YoY

Gross Profit

$264M97.6% margin

Operating Income

-$148M-54.8% margin

Net Income

-$247M-91.2% margin

EPS (Diluted)

$-1.33

Cash Flow

Operating Cash Flow

-$162M

Free Cash Flow

-$163M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$550M

Total Liabilities

$845M

Stockholders' Equity

-$295M

Cash & Equivalents

$305M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$271M	$157M	+72.3%
Gross Profit	$264M	$150M	+76.3%
Operating Income	-$148M	-$178M	+16.5%
Net Income	-$247M	-$184M	-34.3%